ZA200400837B - Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. - Google Patents
Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. Download PDFInfo
- Publication number
- ZA200400837B ZA200400837B ZA200400837A ZA200400837A ZA200400837B ZA 200400837 B ZA200400837 B ZA 200400837B ZA 200400837 A ZA200400837 A ZA 200400837A ZA 200400837 A ZA200400837 A ZA 200400837A ZA 200400837 B ZA200400837 B ZA 200400837B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- surgery
- injury
- lasik
- ait
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 30
- 238000001356 surgical procedure Methods 0.000 title claims description 30
- 210000005036 nerve Anatomy 0.000 title claims description 25
- 208000014674 injury Diseases 0.000 title claims description 16
- 230000006378 damage Effects 0.000 title claims description 15
- 208000027418 Wounds and injury Diseases 0.000 title claims description 13
- 230000008733 trauma Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 27
- 210000002569 neuron Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 230000014511 neuron projection development Effects 0.000 claims description 17
- 230000008929 regeneration Effects 0.000 claims description 16
- 238000011069 regeneration method Methods 0.000 claims description 16
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 10
- 206010013774 Dry eye Diseases 0.000 claims description 10
- 210000004087 cornea Anatomy 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 9
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 5
- 229960004135 idebenone Drugs 0.000 claims description 5
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 claims description 4
- -1 CB-1093 Chemical compound 0.000 claims description 4
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims 6
- 229950005455 eliprodil Drugs 0.000 claims 6
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 3
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 claims 3
- 229960002934 propentofylline Drugs 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 27
- 102000007072 Nerve Growth Factors Human genes 0.000 description 21
- 239000003900 neurotrophic factor Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 4
- 101150111783 NTRK1 gene Proteins 0.000 description 4
- 102100033857 Neurotrophin-4 Human genes 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000013010 irrigating solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108090000742 Neurotrophin 3 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 101150056950 Ntrk2 gene Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940021384 salt irrigating solution Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010061213 Iatrogenic injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940035183 bion tears Drugs 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940036266 tears naturale Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000015533 trkA Receptor Human genes 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Use of Compounds for Treating Conditions Resulting from Injury to the Corneal Nerve after
LASIK and Other Ocular Surgeries or Trauma
1. Field of the Invention
The present invention is directed to the use of compounds that promote neuron ) regeneration or neurite outgrowth for the treatment of conditions resulting from injury to ’ corneal nerves following Laser In Situ Keratomileusis (LASIK) or other surgeries where the corneal nerves are damaged. 2. Description of the Related Art
Patients frequently experience a decrease in corneal sensitivity and mild to moderate dry eye after LASIK surgery. In most patients, this is an acute problem lasting for only a few days. However, in a significant number of patients, the problem may persist for several 1s months or more (Yu 2000). This iatrogenic change most likely results from the severing of corneal nerves during surgery (Wilson 2001; Ambrosio & Wilson 2001). Current treatment methods for surgery-induced dry eye include symptomatic reliefs such as the frequent local application of artificial tears, such as Tears Naturale or Bion Tears®, or other artificial moisturizing agents. These treatments reduce discomfort but do not treat the underlying pathology. No acceptable therapy of the decrease in comeal sensitivity is known to the inventors at this time.
Neurotrophic factors are peptide molecules which stimulate or otherwise maintain growth of neuronal tissue. The transport of neurotrophic factors from the brain to the cell body of neurons is essential to the survival of most ocular nerves. Deprivation of neurotrophic factors 2s can induce apoptosis of neurons (Raff ef al. 1993).
The neurotrophin (NT) family of peptides include nerve growth factor (NGF), brain- derived neurotrophic factor (BDNF), NT-3, NT-4/5 and NT-6. They act by binding to the oo WO 03/020281 PCT/US02/23871 neurotrophin receptors (NT-receptors), such as TrkA, TrkB, TrkC and p7SNTR. The Trk receptors are tyrosine kinases. TrkA is selective for NGF, TrkB is selective for both BDNF and
NT-4/5, whereas TrkC is selective for NT-3. After binding, the NT-receptor complex is internalized and transported via the axon to the soma. These receptors undergo ligand-induced s phosphorylation and dimerization, and activate a cascade of Ras protein-mediated signal transduction events that affect multiple vital functions of the neuron (Lewin et al. 1997; Segal er al. 1996; Ebadi er al. 1997; Kaplan ef al. 1997). Thus, these receptors play a fundamental role in the regulation of survival and differentiation of developing neurons and contribute to the maintenance of neuronal machinery in life.
In the ocular tissue, for example, mRNA of both TrkA and TrkB has been observed in retinal ganglion cells (RGC), dopaminergic amacrine cells and the optic nerve. Their expression was shown to be highly regulated during neuronal development (Jelsma et al. 1993;
Rickman et al. 1995; Ugolini et al. 1995; Cellerino et al. 1997). The TrkB receptor-selective ligands, BDNF and NT-4/5, have been shown to be efficacious for the protection of RGC. 1s Numerous studies have shown that these NTs not only improve the survival and neurite outgrowth of RGC in culture, but also significantly reduce axotomy-induced in vivo damage of the optic nerve and RGC, as well as stimulate the growth of axonal branches from regenerating
RGC (Anderson et al. 1974; Quigley et al. 1976; Mansour-Robaey et al. 1994; Meyer-Franke et al. 1995; and Cui ef al. 1994). For example, a single intravitreal injection of 5 pg of BDNF prevented the death of the axotomized ocular nerves when administered during the first five days after injury (Mansour Robaey 1994; Gao et al. 1997).
Ciliary neurotrophic factor (CNTF) and Basic Fibroblast Growth Factor (bFGF) are ’ other neurotrophic factors that support survival of neurons. They are structurally unrelated to neurotrophins. They have also been shown to prevent lesion-induced death of neurons and axons (Mey et al. 1993; Weibel ef al. 1995).
In normal human and rat corneas, neurotrophic factors, such as NGF , were found to be present (Lambiase ef al. 2000). Human and rat corneal epithelial cells produce, store and s release NGF and also express the TrkA receptor (Lambiase ef al. 1998, Lambiase ef al. 2000).
These trophic factors appear to play an important role in the biology of the cornea. In the cornea of TrkA knockout mice, there was a drastic reduction in the number of nerve trunks, branches and thin nerve terminals. The blinking response of these mice to mechanical, thermal and chemical noxious stimuli was also significantly reduced (De Castro et al. 1998).
Thus, neurotrophic factors are important for the health and normal function of the comea. These trophic factors, however, are peptide molecules, and are therefore difficult to exploit pharmaceutically due to bioavailability problems generally resident in the pharmaceutical administration of peptides. What are needed, therefore, are non-peptide molecules which stimulate neurotrophic activity in compromised retinal tissues, without the bioavailability problems attendant to the natural peptides.
The present invention overcomes these and other drawbacks of the prior art by providing compositions and methods for treating conditions resulting from injury to corneal nerves. The compositions comprise one or more compound that promotes neuron regeneration or neurite outgrowth in a pharmaceutically acceptable vehicle.
As used herein, “compounds that promote neuron regeneration or neurite outgrowth” refers to those compounds which increase the in situ production or activity of neurotrophic 2s factors in the ocular tissue, especially the cornea. As used herein, “neurotrophic factor” refers
Co. - WO 03/020281 PCT/US02/23871 to NGF, BDNF, NT-3, NT-4/5, NT-6, CNTF, bFGF or other trophic factors which prevent, treat or ameliorate cornea neuropathy or promotes the re-growth of damaged cornea neurons.
Examples of neurotrophic factor stimulators include: AIT-082 (neotrofin), idebenone, CB- 1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine), SS-701, and KT-711 (all s shown below), ONO-2506, and clenbuterol. The most preferred neurotrophin stimulator of the present invention is AIT-082 (neotrofin). The preceding molecules may be obtained commercially or may be synthesized by methods known to those skilled in the art.
The methods of the present invention comprise administering to a human patient one or more compounds that promote neuron regeneration or neurite outgrowth, such as neurotrophic factor stimulators, for the treatment of conditions resulting from corneal nerve damage due to surgery.
The methods of the present invention are particularly directed to the use of neuron regeneration or neurite outgrowth promoting compounds for the treatment of dry eye, and other conditions resulting from corneal nerve damage, such as a decrease in corneal sensitivity.
The neuron regeneration or neurite outgrowth promoting compounds of the present invention may be contained in various types of pharmaceutical compositions, in accordance with formulation techniques known to those skilled in the art. In general, the neuron regeneration or neurite outgrowth promoting compounds will be formulated in solutions or suspensions for topical ophthalmic or intraocular administration, or as tablets, capsules or solutions for systemic administration (e.g., oral or intravenous). Preferably, the compounds of the invention will be formulated in a solution or suspension for topical ophthalmic application.
LASIK, and other vision-correction surgeries have allowed numerous corrective lens- wearing people to cease their use of corrective lenses. This is advantageous for many ’ s reasons. For people in some professions, such as art, science and construction work, corrective lenses can be a nuisance because of the dirt, paints, and chemicals with which they must work. However, patients frequently experience a decrease in corneal sensitivity and mild to moderate dry eye after LASIK surgery. In most patients, this is an acute problem lasting for only a few days. However, in a significant number of patients, the problem may persist for several months or more (Yu 2000). This problem is most likely the result of injury to the corneal nerves during surgery (Wilson 2001; Ambrosio & Wilson 2001). The present inventors have discovered that treatment of the injured corneal nerves after surgery with compounds that promote neurite outgrowth or that stimulate the regeneration of the severed or injured nerves can shorten the duration of, or reduce the incidence of, dry eye. Such 1s treatment can also attenuate the decrease in corneal sensitivity caused by LASIK or other surgeries in which corneal nerves are damaged.
The present invention is directed at the use of compounds that promote the regeneration of severed nerves and/or neurite outgrowth to treat dry eye and the reduction in corneal sensitivity induced by cornea surgery. The compounds that promote the regeneration of severed neuron or promote neurite outgrowth do so by stimulating the production of, or by increasing the activity of, neurotrophic factors. The compounds used in the present invention may also promote the regeneration of severed nerves and/or neurite outgrowth by direct : action on the injured nerves.
Several neurotrophic factor stimulators have been reported in the scientific literature, 2s for example, AIT-082 (Graul & Castaner 1997), idebenone (Nabeshima et al. 1994), ONO-
2506 (Matsui et al. 1998), NS521 (Gronborg ef al. 1998), CB-1093 (Aimone ef al. 1998) and
Clenbuterol (Culmsee et al. 1998). However, nowhere in the art has it been disclosed or suggested to use neurotrophic factor stimulators to treat dry eye or other iatrogenic injury following Lasik surgery or other surgeries.
Topical ocular formulations of the neuron regeneration or neurite outgrowth promoting compounds are preferred due to ease of administration. Topical ocular formulations may be in solutions or suspensions. In general, topical formulations will contain the active neurotrophin factor stimulator and inert excipients.
The compositions of the present invention may be administered intraocularly following damage to the corneal nerve, such as by LASIK or other surgeries. Compositions useful for intraocular administration will generally be intraocular injection compositions or surgical irrigating solutions. Intraocular injection compositions will generally be comprised of an aqueous solution, e.g., balanced salt irrigating solutions, discussed below.
When the neuron regeneration or neurite outgrowth promoting compounds are 1s administered after surgical procedures, such as through retrobulbar or periocular injection and intraocular perfusion or injection, the use of balanced salt irrigating solutions as vehicles are most preferred. BSS® Sterile Irrigating Solution and BSS Plus® Sterile Intraocular
Irrigating Solution (Alcon Laboratories, Inc., Fort Worth, Texas, USA) are examples of physiologically balanced intraocular irrigating solutions. The latter type of solution is described in United States Patent No. 4,550,022, the entire contents of which are incorporated herein by reference. Retrobulbar and periocular injections are known to those skilled in the art and are described in numerous publications including, for example, Ophthalmic Surgery:
Principles of Practice (1990). The preferred route of administration is ocular topical application. Thus, pharmaceutically effective amounts of the above compounds or their active analogs in solutions or suspensions will be formulated for topical ophthalmic administration by methods known to those skilled in the art.
In general, the doses utilized for the above described purposes will vary, but will be in , an effective amount to prevent, reduce or ameliorate the dry eye or decrease in cornea s sensitivity related to surgery. As used herein, “pharmaceutically effective amount” refers to that amount of a neurotrophin factor stimulator which prevents, reduces or ameliorates the dry eye or decrease in cornea sensitivity related to surgery or trauma. The neurotrophic factor stimulators will generally be contained in the topical formulations or pharmaceutically acceptable carrier contemplated herein in an amount of from about 0.001 to about 10.0% weight/volume (%w/v). Preferred concentrations will range from about 0.1 to about 5.0 % w/v. Topical formulations will generally be delivered to the eye one to six times a day, at the discretion of a skilled clinician. Systemic administration compositions will generally contain about 1-1000 mg of a neurotrophic factor stimulator, and can be taken 1-4 times per day, at the discretion of a skilled clinician.
As used herein, the term “pharmaceutically acceptable carrier” refers to any formulation which is safe, and provides the appropriate delivery of an effective amount of at least one neurotrophic factor stimulator for the desired route of administration.
The compositions of the present invention may contain additional pharmaceutically active agents or may be dosed concurrently with other pharmaceutical compositions. In particular, when treating a mammal for the prevention, treatment or amelioration of conditions resulting from injury to corneal nerves during surgery, the compositions of the present invention may contain additional agents or may be dosed concurrently or sequentially with other agents or compositions. Examples of agents include: artificial tear, artificial moisterizing solutions or other appropriate agents known to those skilled in the art.
Claims (18)
1. A method for the treatment of dry eye resulting from injury to corneal nerves, said method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound that promotes . neuron regeneration or neurite outgrowth.
2. The method of claim 1, wherein the injury to corneal nerves results from surgery.
3. The method of claim 2, wherein the surgery is LASIK surgery.
4. The method of claim 1, wherein the compound may be selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazone) pireridine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.
5. The method of claim 4, wherein the compound is AIT-082.
6. The method of claim 4, wherein the compound is eliprodil.
7. A method for the treatment of decrease in cornea sensitivity resulting from injury to corneal nerves, said method comprising administering to a patient in need thereof a therapeutically effective amount of at least one composition comprising a compound that promotes neuron regeneration or neurite outgrowth.
8. The method of claim 7, wherein the injury to corneal nerves results from surgery.
9. The method of claim 8, wherein the surgery is LASIK surgery.
10. The method of claim 7, wherein the compound may be selected from the group ) consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazone) pireridine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.
11. The method of claim 10, wherein the compound is AIT-082.
12. The method of claim 10, wherein the compound is eliprodil. i
13. A method for the treatment of injury to corneal nerves comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound that promotes neuron regeneration or neurite outgrowth.
14. The method of claim 13, wherein the injury to comeal nerves results from surgery.
15. The method of claim 14, wherein the surgery is LASIK surgery.
16. The method of claim 13, wherein the compound may be selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NSS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazone) pireridine, eliprodil, SRS57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.
17. The method of claim 16, wherein the compound is AIT-082.
18. The method of claim 16, wherein the compound is eliprodil.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31565201P | 2001-08-29 | 2001-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400837B true ZA200400837B (en) | 2005-02-02 |
Family
ID=23225436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200400837A ZA200400837B (en) | 2001-08-29 | 2004-02-02 | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1420791A4 (en) |
JP (1) | JP2005502678A (en) |
CN (1) | CN1549718A (en) |
AR (1) | AR036194A1 (en) |
BR (1) | BR0212151A (en) |
CA (1) | CA2455896A1 (en) |
MX (1) | MXPA04001255A (en) |
PL (1) | PL368565A1 (en) |
WO (1) | WO2003020281A1 (en) |
ZA (1) | ZA200400837B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091662A1 (en) * | 2003-04-18 | 2004-10-28 | Senju Pharmaceutical Co. Ltd. | Agent for repairing corneal perception |
ES2234428B1 (en) * | 2003-12-09 | 2006-11-01 | Universidad Miguel Hernandez | COMPOUNDS FOR THE TREATMENT OF THE DROUGHT OF THE OCULAR SURFACE CAUSED BY THE PHOTO-REFRECTIVE SURGERY. |
CN1997381B (en) * | 2004-04-23 | 2011-06-08 | 千寿制药株式会社 | Corneal neuritogenesis promoter containing PACAP and its derivative |
JP4932480B2 (en) * | 2004-06-03 | 2012-05-16 | 千寿製薬株式会社 | Corneal sensory recovery agent containing amide compound |
US20090082455A1 (en) | 2005-03-15 | 2009-03-26 | Ono Pharmaceutical Co. Lted | Therapeutic agent for ophthalmic disease |
CN113350326B (en) * | 2021-07-28 | 2023-03-17 | 爱尔眼科医院集团股份有限公司 | Application of compound LM22B-10 in preparation of corneal epithelium and nerve injury treatment drugs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
FR2672213B1 (en) * | 1991-02-05 | 1995-03-10 | Sanofi Sa | USE OF 4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINIC DERIVATIVES AS SENSORS OF FREE RADICALS. |
US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
US5604244A (en) * | 1995-06-07 | 1997-02-18 | Alcon Laboratories, Inc. | Intraocular irrigating solution containing a polyamine antagonist |
TWI246421B (en) * | 1998-12-03 | 2006-01-01 | Alcon Mfg Ltd | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
WO2001085152A2 (en) * | 2000-05-10 | 2001-11-15 | Alcon, Inc. | R-eliprodil for treating glaucoma |
-
2002
- 2002-07-23 BR BR0212151-4A patent/BR0212151A/en not_active Application Discontinuation
- 2002-07-23 MX MXPA04001255A patent/MXPA04001255A/en not_active Application Discontinuation
- 2002-07-23 CA CA002455896A patent/CA2455896A1/en not_active Abandoned
- 2002-07-23 EP EP02756710A patent/EP1420791A4/en not_active Withdrawn
- 2002-07-23 JP JP2003524588A patent/JP2005502678A/en not_active Withdrawn
- 2002-07-23 CN CNA028168682A patent/CN1549718A/en active Pending
- 2002-07-23 WO PCT/US2002/023871 patent/WO2003020281A1/en not_active Application Discontinuation
- 2002-07-23 PL PL02368565A patent/PL368565A1/en unknown
- 2002-07-30 AR ARP020102872A patent/AR036194A1/en unknown
-
2004
- 2004-02-02 ZA ZA200400837A patent/ZA200400837B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1420791A4 (en) | 2004-09-15 |
EP1420791A1 (en) | 2004-05-26 |
MXPA04001255A (en) | 2004-05-27 |
AR036194A1 (en) | 2004-08-18 |
JP2005502678A (en) | 2005-01-27 |
CN1549718A (en) | 2004-11-24 |
BR0212151A (en) | 2004-08-24 |
WO2003020281A1 (en) | 2003-03-13 |
CA2455896A1 (en) | 2003-03-13 |
PL368565A1 (en) | 2005-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010017541A2 (en) | Compositions and methods for treatment of neurodegenerative disease | |
DE60206289T2 (en) | USE OF BIBN4096 IN COMBINATION WITH OTHER MIGRANTS FOR THE TREATMENT OF MIGRAINE | |
JP2009001591A (en) | Deprenyl compound for treatment of glaucoma | |
DE69924284T2 (en) | USE OF STIMULATORS OF NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEEGENERATIVE OPHTHALMIC DISEASES | |
ZA200400837B (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. | |
RU2432948C2 (en) | Application of soluble guanilate-cyclase activators for treatment | |
JP2016026229A (en) | Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use | |
US20040162315A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma | |
RU2134107C1 (en) | Preparation "gistokhrom" for treatment of eye retina and cornea inflammatory sicknesses | |
WO2000021531A1 (en) | Remedies for ocular diseases | |
LANGHAM et al. | The action of protriptyline on adrenergic mechanisms in rabbit, primate and human eyes | |
CN105935443A (en) | Pharmaceutical composition for treating diabetic cataract | |
AU2002322700A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma | |
US20050203121A1 (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
JP2004331502A (en) | Optical nerve cell protecting agent | |
RU2224519C2 (en) | Antioxidant and nervous cell growth-stimulating agent | |
Grehn et al. | Neuroprotection in Glaucoma | |
US8106096B2 (en) | Compositions and methods for treatment of optic nerve diseases | |
JP4393863B2 (en) | Optic nerve cell protective agent | |
WO2001056606A1 (en) | Remedies for ophthalmic diseases | |
JP2023042650A (en) | ophthalmic agent | |
CN113350326A (en) | Application of compound LM22B-10 in preparation of corneal epithelium and nerve injury treatment drugs | |
MXPA01002895A (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
KR20070019001A (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
WO2006021166A1 (en) | Procaine combination therapy |